-
A Breakthrough Alliance: IDEAYA and Genentech Join Forces to Target Pancreatic Cancer
NASDAQ: $IDYA A Strategic Leap in Precision Oncology In a significant development for oncology research, IDEAYA Biosciences has officially announced a new clinical trial collaboration with Genentech, a member of the Roche Group. This partnership aims to tackle one of the most challenging areas in cancer treatment: MTAP-deleted, KRAS G12D mutant pancreatic cancer. The Power…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…